At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol C2: Crizotinib in Patients With Tumors With MET Exon 14 Deletion
In Brief
A Phase 2 clinical trial evaluating Biopsy Procedure, Biospecimen Collection, and 2 other interventions for Advanced Lymphoma and 4 related conditions. Active but no longer recruiting, targeting 20 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial tests how well crizotinib works to treat patients with cancers with MET exon 14 deletion genetic changes. Crizotinib is in a group of medications called tyrosine kinase inhibitors. It works by blocking enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow.
Study Details
Timeline
Interventions
Undergo tumor biopsy
Undergo blood sample collection
Given PO
Undergo radiologic evaluation